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The outcome of thoracic endovascular aortic
repair (TEVAR) in patients with renal insufficiency
Grace J. Wang, MD, Ronald M. Fairman, MD, Benjamin M. Jackson, MD, Wilson Y. Szeto, MD,
Alberto Pochettino, MD, and Edward Y. Woo, MD, Philadelphia, Pa
Objective: We sought to determine the effects of renal insufficiency on thoracic endovascular aortic repair (TEVAR)
outcome and to identify predictors for adverse events.
Methods: Eighty-four patients with renal insufficiency (creatinine>1.5 mg/dL) were analyzed from a prospective TEVAR
database from April 1, 1999, to January 1, 2008. Patients were subdivided into groups by creatinine level (mg/dL):
group 1 (1.5-2.0), group 2 (2.0-3.0), group 3 (>3.0), and group 4 (preoperative dialysis-dependent). Demographics,
aneurysm/aortic lesion characteristics, perioperative morbidity, mortality, and follow-up data were compared with 246
control patients (<1.5 mg/dL).
Results: Comorbidities were similar between the renal insufficiency and control groups, except for age (74  8 vs 69  6
years, P< .0002), male gender (73% vs 58%, P< .02), and presence of peripheral vascular disease (56% vs 38%, P< .005).
Mean follow-up was 9 months. The renal insufficiency and control groups had similar aortic pathologies, including
fusiform (51% vs 57%) and saccular aneurysms (27% vs 37%). Overall mean serum creatinine and creatinine clearance did
not worsen during follow-up. Perioperatively, 18 patients (21%) patients required dialysis. Nine patients (11%) presented
a newly acquired need for dialysis. Degree of preoperative renal impairment correlated with increasing dialysis
requirement: group 1, 5% (3 of 55); group 2, 25% (3 of 12); group 3, 38% (3 of 8); and group 4, 100% (9 of 9). Three
patients did not recover baseline renal function. Contrast type (isosmolar vs hyposmolar) and amount (96 8 mL vs 100 
8 mL, P  .33) was similar between the dialysis and no-dialysis groups. Renal insufficiency patients had a statistically
significant higher rate of major adverse events (25% vs 6.9%, P < .00003), 30-day mortality (11% vs 4.4%, P < .05), and
myocardial infarction (6.0% vs 1.0%, P < .013) than controls. One or more major adverse events occurred in 25%,
including stroke (6.0%), myocardial infarction (6.0%), and spinal cord ischemia (4.8%). Predictors for adverse events
included emergency repair (odds ratio, 3.1; 95% confidence interval, 1.1-8.4; P  0.037) and baseline creatinine >2.0
(odds ratio, 5.9; 95% confidence interval, 2.1-16.8; P  .001). Age, gender, adjunctive access, type of aortic pathology,
and number of device components did not adversely affect outcome.
Conclusion: Patients with preoperative renal insufficiency maintain renal function after TEVAR. However, this patient
population may be susceptible to increased adverse events, with emergency repair and baseline creatinine >2.0 mg/dL
serving as strong predictors. ( J Vasc Surg 2009;49:42-6.)The multicenter Gore TAG (W. L. Gore and Associ-
ates, Flagstaff, Ariz) pivotal trial led to United States Food
and Drug Administration approval for endovascular repair
of descending thoracic aortic aneurysms in March 2005 in
theUnited States, although pivotal trials were conducted as
early as 1998 in Europe.1,2 Since then, thoracic endovas-
cular aortic repair (TEVAR) has had more widespread
applicability and is increasingly being used for other aortic
pathologies such as complicated type B dissection,3-5 trau-
matic transection,6-8 and aneurysmal disease extending
into the arch or visceral segment requiring debranching
procedures.9-11
Long regarded as the less morbid approach to treating
thoracic aortic pathologies, the recent article summarizing
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42the phase II, 5-year results of the TAG study rather defin-
itively showed a reduction in aneurysm-related death with-
out a compromise in overall survival.12 Given these findings
as well as continued advances in device design and delivery,
TEVAR is positioned to become the preferred modality of
treatment of diverse aortic pathologies in patients with
suitable anatomy. With this increase in applicability is a
need for risk stratification to help predict adverse events and
potentially improve outcome.
Patients with renal insufficiency are recognized as a
subset of patients prone to perioperative events13,14 and
have been noted to have a higher cardiovascular morbidity
and mortality15 attributable to the systemic effects of ath-
erosclerosis as well as elevated circulating levels of angio-
tensin II.16 We sought to determine whether preoperative
renal insufficiency affected outcome in patients undergoing
TEVAR and attempted to identify risk factors for adverse
outcome in this subset of patients. In addition, we studied
the effect of TEVAR on renal function in this population.
METHODS
A prospective database of TEVAR patients entered from
April 1, 1999, to January 1, 2008, was retrospectively re-
viewed. Patients undergoing hybrid procedures were ex-
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with renal insufficiency were defined by a serum creatinine
level of1.5 mg/dL, and the control group, by creatinine of
1.5 mg/dL. The patients with renal insufficiency were
further subdivided into four groups by serum creatinine
level: group 1, 1.5 to 2.0; group 2, 2.0 to 3.0; group 3,
3.0 mg/dL, and group 4, dialysis-dependent preopera-
tively. Inclusion criteria consisted of a fusiform aneurysm
diameter5.0 cm in size, a saccular aneurysm of any size, a
ruptured aneurysm of any size, type B dissection with
malperfusion, and traumatic transection. All protocols and
procedures were approved by the FDA and the Institu-
tional Review Board with written informed consent.
Demographic information, aortic lesion/pathology,
and perioperative morbidity/mortality were analyzed and
compared between patients with and without renal insuffi-
ciency. Major adverse events were defined as death, stroke,
spinal cord ischemia (SCI), or myocardial infarction (MI).
The effect of TEVAR on renal function was assessed by
recording serum creatinine levels in the preoperative, peri-
operative (stable creatinine before discharge), and follow-up
periods (range, 1-24 months). Creatinine clearance was esti-
mated using the Cockcroft-Gault equation, which helps to
account for differences due to age, gender, and weight:
CrCl male (140 age) weight ⁄ (SCr 72)
CrCl female [(140 age)weight ⁄ (SCr72)]0.85
The development of the need for hemodialysis was
recorded. The amount and type of contrast used for the
procedure was also analyzed.
Data analysis. Comparison of continuous variables be-
tween groups was made using the t test. Comparison of
categoric variables between groups was made using the Fisher
exact test (two-tailed). Analysis of variance (ANOVA) was
used to compare continuous variables among three or more
groups. Logistic regression analysis was used to help deter-
mine predictors for major adverse events in the renal insuf-
ficiency population. The Pearson correlation coefficient
Table I. Patient demographics and comorbidities
Variable
Cr  1.5
mg/dL
Cr  1.5 mg/dL
(control) P
Patients, No. 84 246
Age, mean  SD, y 74  8 69  6 .0002a
Male, % 73 58 .02a
Hypertension, % 92 89 .68
COPD/tobacco use, % 67 57 .13
Hypercholesterolemia, % 61 55 .38
CAD, % 57 48 .17
Prior AAA repair, % 27 22 .37
PVD, % 56 38 .005a
Diabetes mellitus, % 31 23 .19
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary
disease; Cr, creatinine; PVD, peripheral vascular disease; SD, standard devi-
ation.
aDenotes statistically significant difference.was used to determine a relationship between two groups.A two-tailed P  .05 was considered to be statistically
significant.
RESULTS
Patients and demographics. From April 1, 1999, to
January 1, 2008, 390 patients underwent TEVAR at our
institution. Hybrid procedures were excluded from analy-
sis. The 330 patients with complete records were subdi-
vided into 84 patients with renal insufficiency and 246
without renal insufficiency. Mean follow-up was 9 months
(range, 1-24 months). Patients in the renal insufficiency
cohort were significantly older (74 8 vs 69 6 years, P
.0002), more likely to be men (73% vs 58%, P  .02), and
more likely to carry a diagnosis of peripheral vascular dis-
ease (56% vs 38%, P  .005) compared with the control
group. The two groups were otherwise similar with respect
to comorbidities (Table I). Fusiform aneurysms were the
most common aortic lesion in both groups (51% and 57%),
with saccular aneurysms the next most common (27% and
37%). Because only complicated type B aortic dissections
were treated, all patients in this group had a creatinine1.5
mg/dL. Both groups had a similar percentage of emer-
gency cases (39% vs 33%, P  .43). The use of adjunctive
access between groups was not statistically significant (Ta-
ble II).
Renal function over time. Serum creatinine did not
worsen perioperatively or at follow-up in any of the groups
Fig 1. Serum creatinine levels over time by patient groups. Con-
trol, Serum creatinine 1.5 mg/dL;Group 1, 1.5 to 2.0;Group 2,
2.0 to 3.0; Group 3, 3.0 mg/dL; Group 4, dialysis-dependent
preoperatively. Results are presented with the standard deviation.
Table II. Anatomic and clinical features
Feature
Cr 1.5
mg/dL
Cr 1.5
mg/dL P
Fusiform aneurysm, % 51 57 .42
Saccular aneurysm, % 27 37 .11
Dissection/transection, % 22 . . . N/A
Emergency case, % 39 33 .43
Adjunctive access, % 21 18 .52
Cr, creatinine; N/A, not applicable.(P  .46; Fig 1). In fact, the group 3 patients exhibited an
JOURNAL OF VASCULAR SURGERY
January 200944 Wang et aloverall improvement in renal function (P  .02). Six of
eight patients in group 3 had type B dissections presenting
with malperfusion, thus accounting for the increase in renal
function. These results were further substantiated by calcu-
lating the creatinine clearance (Fig 2). Again, renal function
was preserved in all groups, both perioperatively as well as
at late follow-up, with improvement of renal function
noted in group 3 patients.
Perioperative dialysis was required in 18 of 84 patients
(21%), and nine had a newly acquired need for dialysis. The
degree of preoperative renal impairment correlated with
increasing dialysis requirement (r  0.92, P  .03; Table
III). Nevertheless, only three patients (2 from group 2, 1
from group 3) did not recover baseline renal function. One
patient from group 2 had had a prior nephrectomy for renal
cell carcinoma and underwent a renal stent placement
during the index procedure due to flap encroachment on
the renal artery ostia. The other patient from group 2 had
renal artery stenosis as well as congestive heart failure. The
patient from group 3 had a complicated postoperative
course marked by myocardial infarction and development
of postoperative ileus and worsening abdominal examina-
tion prompting an exploratory laparotomy, which proved
to be negative. Interestingly, contrast type (isosmolar vs
hyposmolar) and contrast amount (96  8 mL vs 100  8
mL) did not differ between the groups with and without
Fig 2. Creatinine clearance over time by patient groups. Control,
Serum creatinine 1.5 mg/dL; Group 1, 1.5 to 2.0; Group 2, 2.0
to 3.0;Group 3,3.0 mg/dL;Group 4, dialysis-dependent preop-
eratively. Results are presented with the standard deviation.
Table III. Progression to perioperative dialysis by group
Group Patients on dialysis, No. (%)
Control 0/246 (0)
Group 1 3/55 (5)
Group 2 3/12 (25)
Group 3 3/8 (38)
Group 4 9/9 (100)
Control, Serum creatinine  1.5 mg/dL; Group 1, 1.5-2.0; Group 2,
2.0-3.0;Group 3,3.0 mg/dL;Group 4, dialysis-dependent preoperatively.dialysis (P  .33).Perioperative morbidity and mortality. Patients
with renal insufficiency had a statistically significant higher
rate of major adverse events (25% vs 6.9%, P  .00003),
30-day mortality (11% vs 4.4%, P  .05), and rate of MI
(6.0% vs 1.0%, P  .013). At least one adverse event
occurred in 25% of patients, including stroke, 6.0% (n 5),
MI, 6.0% (n  5), and SCI, 4.8% (n  4). Four of five
stroke patients underwent zone II coverage. Three of four
patients with SCI had undergone prior abdominal aortic
aneurysm (AAA) repair, although three patients had recov-
ered by discharge (Table IV).
Logistic regression analysis was used to determine pre-
dictors for adverse events in the renal insufficiency popula-
tion. Both emergency case (odds ratio, 95% confidence
interval, 1.1-8.4, P  .037) and baseline creatinine 2.0
mg/dL (odds ratio, 5.9; 95% confidence interval, 2.1-16.8,
P  .0001) were strong predictors. Age, gender, type of
aortic pathology, need for adjunctive access, and number of
device components did not adversely affect outcome.
DISCUSSION
Thoracic aortic endografting is becoming the approach
of choice for the treatment of descending thoracic aortic
aneurysms. As experience with other aortic lesions and
pathologies progresses, the applicability of TEVAR will
continue to grow and evolve. Because it is substantially less
morbid, it has led to the inclusion of sicker patients not
normally considered surgical candidates. Risk stratification
is thus an important element of preoperative planning.
Renal insufficiency has been associated with worse out-
come after surgical procedures. Perioperativemortality13,17
and myocardial infarction18 has been shown to be higher in
patients with renal insufficiency after carotid endarterec-
tomy. This has been attributed to the systemic effects of
atherosclerosis. Patients with atherosclerotic renal artery
disease have a greater degree of left ventricular hypertro-
phy, left ventricular diastolic dysfunction, and higher circu-
lating levels of angiotensin II, causing hypertension and an
impaired endothelium-dependent vasodilatory response.19
The effect of renal dysfunction after coronary artery
bypass grafting (CABG) has also been well studied and
reported. A review using the Society of Thoracic Surgeons
National Adult Cardiac database showed that the preoper-
Table IV. Morbidity and mortality in control vs renal
insufficiency groups
Variable
Cr  1.5
mg/dL
Cr  1.5
mg/dL
(control) P
Major adverse event rate, % 25 6.9 .00003a
30-day mortality, % 11 4.4 .05a
Stroke, % 6 3.2 .33
Myocardial infarction, % 6.0 1 .013a
Spinal cord ischemia, % 4.8 2.4 .28
Cr, Creatinine.
aStatistical significance.ative glomerular filtration rate was a powerful predictor for
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sternal wound infection, and increased hospital stay.20
Worsening degree of renal impairment has also been shown
to adversely affect survival, with an estimated 5-year survival
rate of 45% in patients with bilateral renal artery stenosis,
dropping to 18% in patients who are dialysis-dependent.16
This study was undertaken to evaluate the effects of
preoperative renal insufficiency on outcome after TEVAR.
We found that patients with renal insufficiency defined by
serum creatinine level of 1.5 mg/dL had a statistically
significant higher rate of 30-day mortality and MI than the
control group, findings that parallel those described after
carotid endarterectomy and CABG. In addition, major
adverse events defined as the aggregate rate of stroke, SCI,
MI, and 30-day mortality was higher in patients with renal
insufficiency.
A prior study from this institution noted the relation-
ship between proximal landing zone, severity of atheroma
in the arch, and the risk of perioperative stroke.21 Four of
the five patients in this study with stroke underwent zone II
coverage. Unfortunately, preoperative information regard-
ing the arch was only available in two of these patients,
demonstrating mobile atheroma. To our knowledge, no
studies have correlated the presence of mobile atheroma in
the arch with renal insufficiency; this would be the subject
of future study.
Four patients in this study presented with SCI, three of
whom had had prior AAA repair, a known risk factor for
paraplegia after TEVAR.22 Supplanting our results, recent
data from the European Collaborators on Stent-Graft
Techniques for AAA and Thoracic Aortic Aneurysm and
Dissection Repair (EUROSTAR) registry showed that
paraplegia was independently correlated with renal failure
as well as open AAA repair.23
Predictors for adverse events in this study included
emergency repair and baseline creatinine level 2.0 mg/
dL. As a manifestation of end-organ dysfunction from
widespread effects of atherosclerosis, the relationship be-
tween creatinine elevation and adverse events is not unex-
pected. The emergency nature of 30% of the patients in
this study speaks to the acuity of aortic pathology seen at
our institution. Because many of these patients had some
degree of hemodynamic instability (ie, tachycardia), the
increase in myocardial events is not surprising. The hemo-
dynamic instability or threat of impending rupture in these
patients also precluded the use of spinal cord protective mea-
sures, including lumbar drainage and left carotid–subclavian
bypass.
We were also interested in assessing the effect TEVAR
had on renal function in this patient population. Concerns
regarding the effects of nephrotoxic agents and potential
embolic events due to stent graft proximity to the renal
artery orifices led to a series of studies documenting the
effects of EVAR on renal function. Alsac et al24 reported a
10% decline in creatinine clearance after EVAR 1 year
postoperatively, with no difference noted between suprare-
nal or infrarenal fixation. Greenberg et al25 similarly
showed a decrement in renal function 12 months postop-eratively, although this effect was transient. Parmer et al26
evaluated the effect of EVAR on patients with chronic renal
insufficiency, and although the differences were not statis-
tically significant, there was a similar decrease in renal
function over time.6
TEVAR, however, differs fromEVAR inmany respects,
which may explain why renal function was preserved in this
study. The more proximal nature of landing zones makes
stroke and SCI of greater concern than renal artery embo-
lization. Because of the lack of balloon-catheter manipula-
tion in the vicinity of the renal artery orifices, the embolic
risk should be markedly diminished. In addition, the
amount of contrast required for TEVAR is likely less than
that for EVAR, particularly with the use of modular bifur-
cated prostheses for repair of AAA. Indeed, the overall
average volume required in our series was 99 mL, in con-
trast to the 134 mL for EVAR previously reported by our
institution.26 In addition, the inclusion of dissection pa-
thology in this study perhaps decreased the number of
potential atheroembolic events that might have been ob-
served with thrombus-laden degenerative aneurysms. In-
deed, renal function not only did not deteriorate in com-
plicated dissection patients but, rather, improved over time.
Renal protective measures used by our institution in-
cluded pretreatment with acetylcysteine after 2000 and
pretreatment with acetylcysteine and sodium bicarbonate
solution after 2004. A 600-mg oral dose of acetylcysteine
was administered twice daily the day before and the day of
the procedure. The sodium bicarbonate solution (dextrose
5% with 154 mEq of sodium bicarbonate/L) was either
administered at 3 mL/kg/h 1 hour before the procedure,
followed by 1 mL/kg/h 6 hours after the procedure, or
alternatively for those patients with a history of congestive
heart failure, was administered at a maintenance rate for a
minimum of 12 hours preoperatively and for 6 hours
postoperatively. Isosmolar, noniodinated contrast was used
intraoperatively in patients with creatinine levels 1.5
mg/dL after 2003. The advantages of limiting nephrotoxic
contrast agents preoperatively with the use of magnetic
resonance angiography initially seemed attractive,27 but the
recognition of nephrogenic systemic fibrosis occurring after
gadolinium exposure has limited its usefulness in the renal
insufficiency population. Contrast-enhanced computed to-
mography imaging is thus preferred preoperatively because
it provides themost accurate anatomic information without
the risk of nephrogenic systemic fibrosis, and, in our expe-
rience, has not caused a decrement in renal function. Post-
operatively, the use of noncontrast computed tomography
as well as plain radiographs allow for measurement of
aneurysm sac diameter as well as detection of any stent
fractures or migration.
CONCLUSIONS
Patients with preoperative renal insufficiency preserve
renal function after TEVAR with rare progression to dialysis-
dependence long-term. However, this patient population
may be susceptible to increased adverse events, with emer-
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